Introduction
============

Thyroid carcinoma, accounting for nearly 1% of all the cancers, is the most common malignancy in the endocrine organs.[@b1-ott-10-3261] Traditionally, thyroid carcinomas are classified into papillary thyroid cancer (PTC), follicular thyroid cancer, medullary thyroid cancer, poorly differentiated thyroid cancer and anaplastic thyroid cancer, based on histopathology.[@b2-ott-10-3261] In China, it has been reported that 90 per 100,000 people were diagnosed with thyroid cancer and 6.8 people died among these patients.[@b3-ott-10-3261] In USA, it has been estimated that 1,980 people died of the disease in 2016[@b4-ott-10-3261] and there will be 64,300 new patients of thyroid cancer. The diagnosis of thyroid cancer is often based on magnetic resonance imaging, ultrasound, computed tomography, fine needle aspiration and radionuclide imaging. Although various methods are well applied in clinics, patients often have poor outcome. Reports have shown that the patients' age when being diagnosed, sex, tumor size, lymph node, distant metastases and pathologic differentiation of the cancer are the risk factors of prognosis in thyroid cancer.[@b5-ott-10-3261]--[@b8-ott-10-3261]

However, no studies showed the markers had prognostic value in thyroid cancer. Cell proliferative activity is an important factor in cancer biologic behavior. Ki-67, considered as a nuclear antigen, is expressed in all cell nuclei, except those in the G0 phase. Further, MIB-1 acts as a monoclonal antibody which increases against Ki-67. In recent years, Ki-67 has been studied in many cancers, including cervical cancer,[@b9-ott-10-3261] lung cancer,[@b10-ott-10-3261] breast cancer[@b11-ott-10-3261] and thyroid cancer.[@b12-ott-10-3261] It has been reported that Ki-67 is an independent prognostic factor in thyroid cancer patients.[@b13-ott-10-3261] A study predicted that patients with Ki-67 labeling index (LI) \>3% would show a worse cause-specific survival than those with Ki-67 LI \<3%.[@b12-ott-10-3261] However, Gnemmi et al[@b14-ott-10-3261] reported that Ki-67 LI (≥4%) is an independent factor and predictor of cause-specific survival.

Though many studies have demonstrated Ki-67/MIB-1 is expressed in thyroid cancer, there is no systematic literature assessing the relationship between Ki-67/MIB-1 expression and clinical factors in thyroid cancer patients. So, the significance of Ki-67/MIB-1 for prognostication of thyroid cancer remains uncertain. Thus, a literature-based meta-analysis study was performed to evaluate the diagnostic and prognostic values of Ki-67/MIB-1 in thyroid cancer.

Materials and methods
=====================

Studies selection
-----------------

Studies were selected to demonstrate the diagnostic and prognostic values of Ki-67/MIB-1 for thyroid cancer. Electronic literatures were searched in PubMed, EBSCO, EMBASE, ISI Web of Science, WanFang, China National Knowledge Infrastructure and Chinese VIP databases from April 1, 1989 to July 31, 2016. The following keywords were used to identify the related publications: "thyroid cancer", "Ki-67", "MIB-1", "proliferative marker", "proliferative index", "diagnosis", "prognostic", "survival". The eligible studies were selected in accordance with the following criteria: 1) studies should be published in full assays; 2) the goal of the publication was to illustrate the clinical significance of Ki-67/MIB-1 in primary thyroid cancer; 3) sufficient data were used to determine the connection between Ki-67/MIB-1 and clinicopathologic parameters; 4) when the same patient cohort was reported in different publications, only the most complete and recent study was selected in the meta-analysis.

Also, we screened the references from the reviews and identified articles.

Data extraction and assessment of study quality
-----------------------------------------------

Three authors (Deng-hua Pan, Dong-yue Wen and Yi-huan Luo) read the studies carefully and independently. The information of the publications was collected from each study: first author's name, publication date, the number of patients, patient age, country, follow-up time, antibody of testing Ki-67/MIB-1, the method of detecting Ki-67/MIB-1 expression and threshold used for assessing Ki-67/MIB-1 expression positively. True positive, true negative, false positive and false negative were extracted to construct a diagnostic contingency table. Disease-free survival (DFS) or mortality or distant recurrences-free survival was used to measure the effect of Ki-67/MIB-1 expression on survival in thyroid cancer patients. The following clinical parameters were extracted to evaluate the connection between Ki-67/MIB-1 and thyroid cancer aggressiveness: age, tumor size, lymph node metastasis, metastasis status, extrathyroid extension, tumor node metastasis stage. Minimal size of patients and minimal follow-up time are not defined in this meta-analysis. Studies that met the following criteria were excluded: 1) reviews, conference papers, case reports, expertise public opinion, letters, zoopery were not included; 2) studies without sufficient information to calculate the impact of diagnosis, survival and prognosis of Ki-67/MIB-1 in primary thyroid cancer were excluded; 3) studies with duplicated data from similar or the same population were excluded. QUADAS-2 was used to assess the quality of the studies for diagnosis.[@b15-ott-10-3261] Newcastle--Ottawa scale (NOS) was used to assess the quality of the studies for prognosis.[@b16-ott-10-3261] The study with NOS scores ≥6 was identified as a high-quality study and the study with NOS scores \<6 was considered as a low-quality study.

Statistical methods
-------------------

According to the cut-off values, Ki-67/MIB-1 expression was divided into positive and negative groups. The pooled sensitivity and specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR−), diagnostic odds ratio (DOR) and the area under the symmetric receiver operating characteristic curve were used to measure the diagnosis of Ki-67/MIB-1 in thyroid cancer. The odds ratio (OR) and 95% confidence intervals (CIs) were used to estimate the relationship between Ki-67/MIB-1 and clinicopathologic parameters in thyroid cancer patients. When the OR was \>1, it indicated that high Ki-67/MIB-1 was a risk factor in thyroid cancer. Hazard ratio (HR) and 95% CI were calculated to measure the effect of Ki-67/MIB-1 on prognosis. Also, when the HR was \>1, it indicated that high level of Ki-67/MIB-1 was related to worse survival in thyroid cancer patients.

Further, Cochran's *Q*-test was performed to measure heterogeneity. Also, *I*^2^ was calculated to assess the inconsistency of the studies. When *I*^2^ was over 50% or chi-squared *P*-value was \>0.1, fixed-effect meta-analysis was performed; otherwise, random-effect meta-analysis was used when there was less or no heterogeneity (when *I*^2^ was less than 50% or chi-squared *P*-value was \<0.1). MetaDiSc was used to measure the diagnosis of Ki-67/MIB-1 in thyroid cancer. STATA12.0 was used to calculate the progression and prognosis of Ki-67/MIB-1 in thyroid cancer. The potential publication bias was investigated through funnel plot and by computation of Begg's test. When the *P*-value was \<0.05, it was considered significant.

Results
=======

Description of studies
----------------------

The flow chart of search process is presented in [Figure 1](#f1-ott-10-3261){ref-type="fig"}. One thousand one hundred and sixty-two relevant studies were identified. After reviewing the abstracts and full text, only 51 studies[@b1-ott-10-3261],[@b12-ott-10-3261],[@b14-ott-10-3261],[@b17-ott-10-3261]--[@b64-ott-10-3261] were found to be eligible and were included in the meta-analysis. The characteristics of these articles are summarized in [Tables 1](#t1-ott-10-3261){ref-type="table"}[](#t2-ott-10-3261){ref-type="table"}--[3](#t3-ott-10-3261){ref-type="table"}. [Table 1](#t1-ott-10-3261){ref-type="table"} gives the main information of the studies included in diagnosis. Thirty-seven studies detecting the diagnostic value of Ki-67/MIB-1 in thyroid cancer were included in our analysis, including 4,818 samples (2,601 cases and 2,217 controls). The quality assessment of the included studies in diagnosis is shown in [Figure 2](#f2-ott-10-3261){ref-type="fig"}. The risks of bias in "index test" and "reference standard" were unclear in this meta-analysis. [Table 2](#t2-ott-10-3261){ref-type="table"} shows the correlation between clinicopathologic parameters and Ki-67/MIB-1, including 4,375 samples (1,317 cases and 3,058 controls). As shown in [Table 3](#t3-ott-10-3261){ref-type="table"}, a total of 10 studies reporting the relation between Ki-67/MIB-1 and thyroid cancer patient survival were included, of which three studies had data on DFS, seven on mortality and only one on distant recurrences-free survival (DRFS). The studies included in survival analysis had 1,083 samples. The age of patients ranged from 45 to 64.8 years, and the median follow-up time ranged from 68 months to 20 years. Immunohistochemistry (IHC) was used to detect the expression of Ki-67/MIB-1 in all the included studies. The cut-off value ranged from 1% to 10%. The quality assessment of the studies included in prognosis is shown in [Table 4](#t4-ott-10-3261){ref-type="table"}.

Effect of Ki-67/MIB-1 on diagnosis
----------------------------------

Due to heterogeneity, random-effect model was used to calculate the overall performance of Ki-67/MIB-1 in thyroid tissues in diagnosing thyroid cancer. Ki-67/MIB-1 was found to be a valuable diagnostic factor for thyroid cancer. The pooled sensitivity was 0.61 (95% CI: 0.59--0.63; [Figure 3A](#f3-ott-10-3261){ref-type="fig"}) and specificity was 0.75 (95% CI: 0.74--0.77; [Figure 3B](#f3-ott-10-3261){ref-type="fig"}). The pooled LR+ was 3.19 (95% CI: 2.30--4.42; [Figure 3C](#f3-ott-10-3261){ref-type="fig"}) and the pooled LR− was 0.43 (95% CI: 0.35--0.54; [Figure 3D](#f3-ott-10-3261){ref-type="fig"}). The pooled DOR of Ki-67/MIB-1 was 8.54 (95% CI: 5.03--14.49; [Figure 4](#f4-ott-10-3261){ref-type="fig"}). The area under the symmetric receiver operating characteristic curve was 0.804 (standard error =0.031; [Figure 5](#f5-ott-10-3261){ref-type="fig"}). For Ki-67/MIB-1, the summary indexes of 37 studies are displayed in forest plots. High heterogeneity was found in sensitivity (*I*^2^=94.5%, *P*\<0.001) and specificity (*I*^2^=94.7%, *P*\<0.001). Also, subgroup analysis was performed to identify the possible reasons for heterogeneity. There were 12 studies with Ki-67/MIB-1 cut-off value ≤5%, which revealed a pooled sensitivity of 0.70 (95% CI: 0.67--0.73), specificity of 0.80 (95% CI: 0.77--0.83) and DOR of 7.49 (95% CI: 3.61--15.52). Fifteen studies had Ki-67/MIB-1 cut-off value of 10%, a pooled sensitivity of 0.56 (95% CI: 0.53--0.59), specificity of 0.67 (95% CI: 0.63--0.70) and DOR of 7.73 (95% CI: 2.68--22.30). There were eight studies with a cut-off value \>10%, and the pooled sensitivity, specificity and DOR were 0.78 (95% CI: 0.75--0.81), 0.79 (95% CI: 0.74--0.84) and 15.40 (95% CI: 3.41--69.62), respectively. In the subgroup analysis of PTC, the results showed that the pooled sensitivity, specificity and DOR were 0.63 (95% CI: 0.60--0.65), 0.74 (95% CI: 0.72--0.76) and 8.22 (95% CI: 4.08--16.56), respectively. In the subgroup analysis of papillary thyroid microcarcinoma (PTMC), the results showed that the pooled sensitivity, specificity and DOR were 0.45 (95% CI: 0.37--0.52), 0.86 (95% CI: 0.77--0.92) and 4.76 (95% CI: 2.48--9.17), respectively ([Table S1](#SD1-ott-10-3261){ref-type="supplementary-material"}).

Associations of Ki-67/MIB-1 with clinicopathologic parameters
-------------------------------------------------------------

[Table 2](#t2-ott-10-3261){ref-type="table"} shows the main results of the effects value of Ki-67/MIB-1 on clinicopathologic parameters in thyroid cancer patients. The results suggested that older patients (\>45 years old) had high level of Ki-67/MIB-1 with a pooled OR of 1.71 (95% CI: 1.14--2.57, *P*=0.010; *I*^2^=0.00%, *P*=0.806; [Figure 6A](#f6-ott-10-3261){ref-type="fig"}). The level of Ki-67/MIB-1 was higher in large tumor size (\>4 cm) than in small-sized tumor (\<4 cm; pooled OR =1.86, 95% CI: 1.17--2.96, *P*=0.008; *I*^2^=2.00%, *P*=0.395; [Figure 6B](#f6-ott-10-3261){ref-type="fig"}). Overall, 15 studies had data to estimate the relationship between Ki-67/MIB-1 and lymph node metastasis. The pooled OR estimated from 15 studies indicated that Ki-67/MIB-1 was lower in negative lymph node metastasis than in positive lymph node metastasis (pooled OR =2.49, 95% CI: 1.42--4.39, *P*=0.002; *I*^2^=50.20%, *P*=0.014; [Figure 6C](#f6-ott-10-3261){ref-type="fig"}). Also, the association between Ki-67/MIB-1 and metastasis status was calculated and the combined OR was 6.96 (95% CI: 2.46--19.69, *P*\<0.001; [Figure 6D](#f6-ott-10-3261){ref-type="fig"}). The combined OR for tumor node metastasis stage was 6.56 (95% CI: 3.80--11.33, *P*\<0.001; *I*^2^=0.00%, *P*=0.960), suggesting that overexpression of Ki-67/MIB-1 was significantly correlated with advanced stage ([Figure 6E](#f6-ott-10-3261){ref-type="fig"}). In addition, four studies provided insufficient information to estimate the effect of extrathyroid extension. The pooled OR was 1.91 (95% CI: 1.27--2.87, *P*=0.002; [Figure 6F](#f6-ott-10-3261){ref-type="fig"}).

Impact of Ki-67/MIB-1 expression on survival in thyroid cancer
--------------------------------------------------------------

Furthermore, three studies assessing the association of Ki-67/MIB-1 expression on DFS were identified in this meta-analysis. The combined HR was 5.19. It was demonstrated that overexpression of Ki-67/MIB-1 was associated with worse DFS in thyroid cancer by fixed-effect model (95% CI: 3.18--8.46, *P*\<0.001; *I*^2^=36.1%, *P*=0.209; [Figure 7](#f7-ott-10-3261){ref-type="fig"}). The meta-analysis showed overexpression of Ki-67/MIB-1 had effect on mortality (HR =3.56, 95% CI: 1.17--10.83, *P*=0.025) in eight studies, with heterogeneity (*I*^2^=73.5%, *P*\<0.001; [Figure 8](#f8-ott-10-3261){ref-type="fig"}). Worsened mortality was found among patients with Ki-67/MIB-1 cut-off value \>10% (HR =34.08, 95% CI: 3.81--305.00, *P*=0.002) by subgroup analysis. Nevertheless, when Ki-67/MIB-1 was more than 5%, the patients were afflicted with poor mortality (HR =28.06, 95% CI: 6.68--117.87, *P*\<0.001) in thyroid cancer. No connection was found between Ki-67/MIB-1 and thyroid cancer when Ki-67/MIB-1 was less than 5% (HR =1.98, 95% CI: 0.65--6.06, *P*=0.230). In subgroup analysis, no significant association was found between medullary thyroid cancer and mortality (HR =0.96, 95% CI: 0.24--2.16). In addition, no significant relationship was observed between PTC and mortality (HR =1.47, 95% CI: 2.23--5.18; [Table S2](#SD2-ott-10-3261){ref-type="supplementary-material"}).

Publication bias
----------------

The Begg's test and funnel plot showed that there was no evidence of publication bias present among all the analyses in our meta-analysis (all *P*\>0.05; [Figures 9](#f9-ott-10-3261){ref-type="fig"} and [10](#f10-ott-10-3261){ref-type="fig"}).

Discussion
==========

Cell proliferative activity is regarded as an important factor for evaluating the biologic behavior of cancer cells. It is a key process in the development of tumors when the balance between cell death and proliferation is destroyed. We used IHC to detect cell cycle-specific antigens and this method can assess the proliferative activity of cells. Ki-67/MIB-1 is the most widely used marker for assessing the proliferative capacity of tumor cells. Increased expression of Ki-67/MIB-1 has been linked to increased invasiveness in many cancers.[@b10-ott-10-3261],[@b65-ott-10-3261]--[@b67-ott-10-3261] Many meta-analyses have shown that high expression of Ki-67/MIB-1 contributed to poor survival in many tumors.[@b68-ott-10-3261]--[@b72-ott-10-3261] However, there is no consensus on the association between high level of Ki-67/MIB-1 and thyroid cancer at present. Meta-analysis is a systematical method applied widely to evaluate the prognostic indicators in different trials. Thus, in this meta-analysis, we explored the diagnosis and prognosis of Ki-67/MIB-1 expression in thyroid cancer.

In our study, we found the valuable predicting effect of Ki-67/MIB-1 for the diagnosis of thyroid cancer with a high accuracy for Chinese. In clinical practice, detecting Ki-67/MIB-1 expression may contribute to diagnosing thyroid cancer when combined with clinical symptoms, laboratory examinations and other radiologic imaging. Our analysis demonstrated that patients with overexpression of Ki-67/MIB-1 seemed to have a poor survival in thyroid cancer. Also, Ki-67/MIB-1 was found to be associated with tumor size, lymph node metastasis, metastasis status, extrathyroid extension and other clinicopathologic parameters. However, the mechanism of Ki-67/MIB-1 in thyroid cancer is still unclear. Ki-67/MIB-1 as a cellular marker has a positive effect on cell proliferation. Ki-67/MIB-1 expression detected by IHC can evaluate tumor cell proliferation. A previous study confirmed that Sp1 plays an important role in regulation of Ki-67/MIB-1 gene expression.[@b73-ott-10-3261] Another study pointed out that E2F2 transcription factor was positively correlated with Ki-67/MIB-1 expression in human glioblastoma[@b74-ott-10-3261] and E2F1--3 factors are the transcriptional activator in tumor progression and the retinoblastoma tumor suppressor pathway regulates E2F1--3 factors which could control cellular proliferation.[@b75-ott-10-3261]

In this meta-analysis, heterogeneity existed among the studies. Heterogeneity was still a potential problem which affected the meta-analysis results, though random-effect models were used to analyze the data. Meanwhile, in order to reduce heterogeneity, only the studies with the method of IHC to detect Ki-67/MIB-1 were included in this meta-analysis. However, evaluation standards, study location, number of patients, sex and age of patients were different, which contributed to the heterogeneity. Also, various cut-off values were used to define thyroid cancer with Ki-67/MIB-1 positive expression by different investigators, which potentially contributed to the heterogeneity. So, it is difficult to apply a standard critical value in clinical practice. Spyratos et al[@b76-ott-10-3261] found that few tumors with low proliferation rate were under misclassification when the cut-off value of Ki-67/MIB-1 was 10%, and it is acceptable to identify a highly proliferative tumor with a Ki-67/MIB-1 cut-off value of 25%. In this meta-analysis, the cut-off values of Ki-67/MIB-1 ranged from 0.5% to 25%. Therefore, different Ki-67/MIB-1 cut-offs may cause heterogeneity. Higher sensitivity, specificity and DOR were found in patients with cut-off value \>10% by diagnostic subgroup analysis. Furthermore, those patients may have worse mortality. Given the small size of studies included in mortality analysis, further research with larger sample size would be needed to explore the impact of KI-67/MIB-1 on mortality. Besides, HRs were extracted from survival curves or calculated from data which might be less than another variance. Most of the studies included in diagnosis were from China; however, most of the studies related to DFS and mortality were from outside of China. We found that Ki-67/MIB-1 had a diagnostic value in Chinese. However, we did not have enough data to calculate the relationship between Ki-67/MIB-1 and mortality for Chinese. So, regional variation may become a score of heterogeneity. Besides, due to several types of thyroid cancer dealt with in the same study, we conducted subgroup analysis in this meta-analysis. Ki-67/MIB-1 had diagnostic effect on different thyroid cancer types. We did not find significant association between Ki-67/MIB-1 and different thyroid cancer types.

Despite the above limitations, the current meta-analysis proves the associations between high Ki-67/MIB-1 and tumor deterioration, poor DFS and increased mortality in patients with thyroid cancer. In conclusion, we showed that high expression of Ki-67/MIB-1 was significantly connected with tumor size, lymph metastasis, metastasis status, extrathyroid extension and poor prognosis of thyroid cancer in this study.

Conclusion
==========

Our meta-analysis shows that Ki-67/MIB-1 may be a biomarker for clinical deterioration in Chinese and has an effect on prognosis in thyroid cancer among non-Chinese. Therefore, detection of Ki-67/MIB-1 in the clinic will be beneficial to the treatment and prognostic assessment for thyroid cancer patients. However, well-designed prospective studies are necessary to further confirm our results.

Supplementary materials
=======================

###### 

Subgroup analysis evaluating the diagnostic value of Ki-67/MIB-1 in thyroid cancer

  Groups       No of studies   Pooled sensitivity (95% CI)   Pooled specificity (95% CI)   DOR (95% CI)
  ------------ --------------- ----------------------------- ----------------------------- ---------------------
  Cut-off, %                                                                               
    ≤5         12              0.70 (0.67--0.73)             0.80 (0.77--0.83)             7.49 (3.61--15.52)
   10          15              0.56 (0.53--0.59)             0.67 (0.63--0.70)             7.73 (2.68--22.30)
    \>10       8               0.78 (0.75--0.81)             0.79 (0.74--0.84)             15.40 (3.41--69.62)
  Types                                                                                    
   PTC         21              0.63 (0.60--0.65)             0.74 (0.72--0.76)             8.22 (4.08--16.56)
   PTMC        2               0.45 (0.37--0.52)             0.86 (0.77--0.92)             4.76 (2.48--9.17)

**Abbreviations:** CI, confidence interval; DOR, diagnostic odds ratio; PTC, papillary thyroid carcinoma; PTMC, papillary thyroid microcarcinoma.

###### 

Subgroup analysis evaluating the prognostic value of Ki-67/MIB-1 for mortality in thyroid cancer

  Groups                  Pooled HR   95% CI         Heterogeneity test   Statistical method   
  ----------------------- ----------- -------------- -------------------- -------------------- --------
  Univariate cut-off, %                                                                        
    ≤5                    1.98        0.65--6.06     68.80                0.007                Random
    \>5                   28.06       6.68--117.87   0.00                 0.818                Random
    \<10                  2.73        0.89--8.38     72.20                0.001                Random
  Types                                                                                        
   PTC                    1.47        2.23--5.18     87.10                \<0.001              Random
   MTC                    0.96        0.24--2.16     65.50                0.035                Random

**Abbreviations:** CI, confidence interval; HR, hazard ratio; MTC, medullary thyroid carcinoma; PTC, papillary thyroid carcinoma.

The study was supported by funds from the Guangxi Scientific Research and Technology Development Plan (1598011-4). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the paper.
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![Flow diagram of reviewing and selecting studies.](ott-10-3261Fig1){#f1-ott-10-3261}

![Risk of bias of studies included in diagnosis with QUADAS-2 tool.](ott-10-3261Fig2){#f2-ott-10-3261}

![Forest plots for the accuracy of Ki-67/MIB-1 for the diagnosis of thyroid cancer.\
**Notes:** (**A**) Sensitivity; (**B**) specificity; (**C**) positive LR (LR+); (**D**) negative LR (LR−).\
**Abbreviations:** CI, confidence interval; *df*, degrees of freedom; LR, likelihood ratio.](ott-10-3261Fig3){#f3-ott-10-3261}

![Forest plot of DOR of Ki-67/MIB-1 for the diagnosis of thyroid cancer.\
**Note:** The pooled DOR of Ki-67/MIB-1 for the diagnosis of thyroid cancer was 8.54 (95% CI: 5.03--14.49).\
**Abbreviations:** CI, confidence interval; *df*, degrees of freedom; DOR, diagnostic odds ratio; OR, odds ratio.](ott-10-3261Fig4){#f4-ott-10-3261}

![SROC curve for the accuracy of Ki-67/MIB-1 in the diagnosis of thyroid cancer.\
**Notes:** The area under the SROC curve was 0.804 (SE =0.031). Q\* represents the index to judge the accuracy of the diagnostic experiment.\
**Abbreviations:** AUC, area under the curve; SE, standard error; SROC, symmetric receiver operating characteristic.](ott-10-3261Fig5){#f5-ott-10-3261}

###### 

Forest plots of Ki-67/MIB-1 and clinicopathologic parameters in thyroid cancer patients.

**Notes:** (**A**) Age; (**B**) tumor size; (**C**) lymph node metastasis; (**D**) metastasis status; (**E**) TNM stage; (**F**) extrathyroid extension. Weights are from random-effects analysis.

**Abbreviations:** CI, confidence interval; OR, odds ratio; TNM, tumor node metastasis.
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![Meta-analysis evaluating the association between Ki-67/MIB-1 and DFS (fixed-effect analysis).\
**Note:** The combined fixed-effect HR was 5.19 (95% CI: 3.18--8.46, *P*\<0.001), indicating that high level of Ki-67/MIB-1 was associated with worse DFS.\
**Abbreviations:** CI, confidence interval; DFS, disease-free survival; HR, hazard ratio.](ott-10-3261Fig7){#f7-ott-10-3261}

![Meta-analysis evaluating the association between Ki-67/MIB-1 and mortality (random-effect analysis).\
**Notes:** The pooled fixed-effect HR was 3.56 (95% CI: 1.17--10.83, *P*=0.025), indicating that high level of Ki-67/MIB-1 was associated with increased of risk of mortality. Weights are from random-effect analysis.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio.](ott-10-3261Fig8){#f8-ott-10-3261}

![Assessment of publication bias for clinicopathologic parameters.\
**Notes:** (**A**) Age; (**B**) tumor size; (**C**) lymph node metastasis; (**D**) metastasis status; (**E**) TNM stage; (**F**) extrathyroid extension.\
**Abbreviations:** OR, odds ratio; SE, standard error; TNM, tumor node metastasis.](ott-10-3261Fig9){#f9-ott-10-3261}

![Assessment of publication bias for DFS and mortality.\
**Notes:** (**A**) DFS; (**B**) mortality.\
**Abbreviations:** DFS, disease-free survival; HR, hazard ratio; SE, standard error.](ott-10-3261Fig10){#f10-ott-10-3261}

###### 

Characteristics of studies included in diagnosis

  First author                      Country   Patients   Type of cancer       Type of control                                                      Antibody                               Test method   Threshold, %   TP    FP   FN    TN
  --------------------------------- --------- ---------- -------------------- -------------------------------------------------------------------- -------------------------------------- ------------- -------------- ----- ---- ----- -----
  Horii et al[@b29-ott-10-3261]     Japan     50         PTC, FTC, ATC        Adenomatous goiter, FA                                               Ki-67 monoclonal antibody              IHC           20             276   2    6     15
  Huang et al[@b34-ott-10-3261]     China     160        PTC                  FA, goiter                                                           Mouse monoclonal antibody              IHC           5              103   9    0     128
  Chou et al[@b30-ott-10-3261]      Taiwan    46         PTC, FVPTC           NG, normal tissue                                                    Mouse monoclonal antibody anti-Ki-67   IHC           10             16    2    13    15
  Nie et al[@b35-ott-10-3261]       China     26         PTC                  TA, NG, toxic goiter                                                 Anti-Ki-67                             IHC           25             9     2    5     10
  Liang et al[@b36-ott-10-3261]     China     200        PTC                  NG, TA                                                               Ki-67                                  IHC           25             93    1    7     99
  Gan et al[@b37-ott-10-3261]       China     135        PTC                  Adjacent tissue of thyroid carcinoma, normal tissue, NG, FA          Mouse monoclonal antibody              IHC           10             38    26   7     64
  Wang et al[@b38-ott-10-3261]      China     94         PTC, FTC, MTC, ATC   NG, TA                                                               Ki-67                                  IHC           10             20    0    45    29
  Shang et al[@b39-ott-10-3261]     China     100        PTC, FTC, OCTC       PTA, FTA, OCTA                                                       Anti-Ki-67                             IHC           1.50           42    29   8     21
  Cui et al[@b63-ott-10-3261]       China     87         PTC, FTC             TA, normal tissue                                                    Mouse monoclonal antibody              IHC           10             35    3    19    20
  Feng et al[@b40-ott-10-3261]      China     199        PTC, FTC, MTC        NG, FA, adjacent tissue of thyroid carcinoma                         Ki-67                                  IHC           5              58    16   18    107
  Jin et al[@b64-ott-10-3261]       China     79         PTC, FTC, MTC, ATC   TA, normal thyroid gland tissue beside adenoma                       Mouse monoclonal antibody              IHC           25             39    3    17    20
  Huang et al[@b42-ott-10-3261]     China     70         PTC                  Thyroid hyperplasia, TA                                              Anti-Ki-67                             IHC           10             20    9    10    31
  Li and Du[@b43-ott-10-3261]       China     136        PTC                  NG, NG with adenoma hyperplasia, NGWPH                               Anti-Ki-67                             IHC           10             55    27   0     54
  Hao[@b44-ott-10-3261]             China     236        PTC                  NG, TA                                                               Ki-67                                  IHC           ND             17    2    101   116
  Song et al[@b27-ott-10-3261]      China     592        PTC                  NG, nonmaligant follicular adenoma                                   Mouse monoclonal antibody              IHC           10             179   56   262   95
  Tan et al[@b31-ott-10-3261]       Turkey    39         PTC, FTC             FA                                                                   Ki-67                                  IHC           5              8     10   16    5
  Zeng et al[@b45-ott-10-3261]      China     108        TC                   Normal tissue                                                        Mouse monoclonal antibody              IHC           5              46    11   22    29
  Qin et al[@b46-ott-10-3261]       China     120        PTC                  NG, normal tissue                                                    Anti-Ki-67                             IHC           10             25    78   15    1
  Zhao et al[@b47-ott-10-3261]      China     129        PTC                  Multinodular goiters, follicular adenomas, Hashimoto's thyroiditis   Ki-67                                  IHC           ND             34    22   9     64
  Jiang et al[@b48-ott-10-3261]     China     63         PTC                  TA                                                                   Mouse monoclonal antibody              IHC           10             23    2    12    26
  Yao et al[@b49-ott-10-3261]       China     103        PTC, FTC, MTC, ATC   Normal tissue, NG, FA                                                Mouse monoclonal antibody              IHC           25             60    10   8     25
  Yang et al[@b50-ott-10-3261]      China     55         FTC                  FA                                                                   Mouse monoclonal antibody              IHC           5              15    6    17    17
  Li[@b51-ott-10-3261]              China     246        PTC                  Normal tissue, NG, NGWPH                                             Mouse monoclonal antibody              IHC           10             68    22   8     68
  Shi et al[@b52-ott-10-3261]       China     130        TC                   TA, NG, normal thyroid gland tissue                                  Rabbit monoclonal antibody             IHC           10             42    10   8     70
  Zhang et al[@b28-ott-10-3261]     China     146        PTC                  Multinodular goiter                                                  Ki-67                                  IHC           1.65           57    9    19    61
  Maruta et al[@b23-ott-10-3261]    Japan     108        FC                   FA                                                                   Anti-Ki-67                             IHC           50             47    35   21    5
  Guo et al[@b53-ott-10-3261]       China     117        PTC, FTC, ATC        TA, normal thyroid tissues                                           Anti-Ki-67                             IHC           10             62    2    87    30
  Wang et al[@b54-ott-10-3261]      China     33         PTC                  Hyalinizing trabecular tumor                                         MIB-1                                  IHC           10             20    10   0     3
  Zhou et al[@b55-ott-10-3261]      China     120        PTMC                 TA, NG, Hashimoto's thyroiditis                                      Anti-Ki-67                             IHC           25             34    6    46    34
  Li et al[@b56-ott-10-3261]        China     370        PTC                  Benign thyroid nodule                                                Mouse monoclonal antibody              IHC           1.00           112   48   68    142
  Xu et al[@b57-ott-10-3261]        China     62         PTC                  Thyroid benign tumor                                                 Ki-67                                  IHC           5              32    3    14    13
  Wang et al[@b58-ott-10-3261]      China     95         PTC                  NGWPH                                                                Ki-67                                  IHC           10             26    44   19    6
  Zhou et al[@b24-ott-10-3261]      China     158        PTMC                 NG, TA, Hashimoto's thyroiditis                                      Mouse monoclonal antibody              IHC           25.00          50    7    58    43
  Zhu et al[@b59-ott-10-3261]       China     96         PTC                  Thyroid hyperplasia                                                  Anti-Ki-67                             IHC           5              40    10   24    22
  Li and Pu[@b60-ott-10-3261]       China     150        PTC                  Follicular adenoma, normal tissue                                    Ki-67                                  IHC           5              18    9    32    91
  Li and Zhang[@b61-ott-10-3261]    China     120        PTC                  TA, NG, normal tissue                                                Mouse monoclonal antibody              IHC           10             25    8    5     82
  Feng and Wang[@b62-ott-10-3261]   China     60         MTC                  Adjacent tissue of thyroid carcinoma                                 Mouse monoclonal antibody              IHC           1              36    0    6     18

**Abbreviations:** ATC, anaplastic thyroid cancer; FA, follicular adenoma; FN, false negative; FP, false positive; FTA, follicular thyroid adenoma; FTC, follicular carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; IHC, immunohistochemistry; MTC, medullary thyroid carcinoma; ND, no data; NG, nodular goiter; NGWPH, nodular goiter with papillary hyperplasia; PTA, papillary thyroid adenoma; OCTA, oxyphilical cell thyroid adenoma; OCTC, oxyphilical cell thyroid carcinoma; PTC, papillary thyroid carcinoma; PTMC, papillary thyroid microcarcinoma; TA, thyroid adenoma; TP, true positive; TN, true negative.

###### 

The relationships between Ki-67/MIB-1 expression and clinicopathologic parameters

  Clinicopathologic parameters   Studies (n)   Test group   Control group   Heterogeneity   Meta-analysis model   OR (95% CI)   *P*-value                                                 
  ------------------------------ ------------- ------------ --------------- --------------- --------------------- ------------- ----------- ------------------------ -------------------- ---------
  Age (45 years)                 10            124          303             91              239                   0.00          0.806       Fixed-effect analysis    1.71 (1.14--2.57)    0.01
  Tumor size (4 cm)              5             35           165             76              730                   2.00          0.395       Fixed-effect analysis    1.86 (1.17--2.96)    0.008
  Lymph node metastasis          15            233          345             226             509                   50.20         0.014       Random-effect analysis   2.49 (1.42--4.39)    0.002
  Metastasis status              7             75           133             121             920                   59.80         0.021       Random-effect analysis   6.96 (2.46--19.69)   \<0.001
  TNM stage                      7             113          146             103             247                   0.00          0.96        Fixed-effect analysis    6.56 (3.80--11.34)   \<0.001
  Extrathyroid extension         4             64           225             79              413                   31.30         0.224       Fixed-effect analysis    1.91 (1.27--2.87)    0.002

**Abbreviations:** CI, confidence interval; OR, odds ratio; TNM, tumor node metastasis.

###### 

The features of the studies relating Ki-67/MIB-1 to patients' prognosis

  Type of survival                    First author                      Country   Year   Patients   Age           Median FU    Test method                         Antibody   Threshold, %            HR (95% CI)            *P*-value
  ----------------------------------- --------------------------------- --------- ------ ---------- ------------- ------------ ----------------------------------- ---------- ----------------------- ---------------------- -----------
  DFS                                 Kjellman et al[@b1-ott-10-3261]   Sweden    2003   30         62            146 months   IHC                                 MIB-1      1.85                    4.93 (1.91--12.77)     0.001
  Ito et al[@b12-ott-10-3261]         Japan                             2010      371    49         125 months    IHC          Anti Ki-67 antibody                 1          4.13 (2.19--7.75)       \<0.001                
  Miyauchi et al[@b22-ott-10-3261]    Japan                             2013      390    50.8       88 months     IHC          Anti Ki-67 antibody (clone MIB-1)   \>10       15.33 (4.13--56.96)     \<0.001                
  Mortality                           Wang et al[@b33-ott-10-3261]      Sweden    1996   21         53            10.5 years   IHC                                 Ki-67      5                       0.514 (0.086--3.089)   0.467
  Tisell et al[@b26-ott-10-3261]      Sweden                            2003      36     45         20 years      IHC          Anti-Ki67                           1          2.12 (0.862--5.233)     0.102                  
  Ito et al[@b12-ott-10-3261]         Japan                             2010      371    49         125 months    IHC          Anti Ki-67 antibody                 3          25.64 (2.49--250)       0.006                  
  Chen et al[@b20-ott-10-3261]        USA                               2011      9      64.8       32.5 months   IHC          MIB-1                               5          0.088 (0.008--1.026)    0.052                  
  Miyauchi et al[@b22-ott-10-3261]    Japan                             2013      390    50.8       88 months     IHC          Anti Ki-67 antibody (clone MIB-1)   \>10       34.08 (3.81--305.16)    0.002                  
  Gnemmi et al[@b14-ott-10-3261]      France                            2014      82     ND         68 months     IHC          MIB1                                4          6.126 (1.662--22.574)   0.007                  
  Jovanovic et al[@b32-ott-10-3261]   Macedonia                         2015      20     51.2       73 months     IHC          MIB-1                               6.50       24.25 (3.63--161.99)    0.001                  
  Feng and Wang[@b62-ott-10-3261]     China                             2014      42     53.2       7.8 years     IHC          MIB-1                               1          2.28 (0.61--8.55)       0.228                  
  DRFS                                Gnemmi et al[@b14-ott-10-3261]    France    2014   82         ND            68 months    IHC                                 MIB-1      4                       7.322 (3.141--17.07)   \<0.001

**Abbreviations:** CI, confidence interval; DFS, disease-free survival; DRFS, distant recurrences-free survival; FU, follow-up; HR, hazard ratio; IHC, immunohistochemistry; ND, no data.

###### 

Quality assessment of included studies according to NOS

  Studies                             Selection   Comparability   Outcome   Total                          
  ----------------------------------- ----------- --------------- --------- ------- -- ---- ---- ---- ---- ---
  Kjellman et al[@b1-ott-10-3261]     2003        \*              \*        \*              \*   \*   \*   6
  Feng and Wang[@b62-ott-10-3261]     2015        \*              \*        \*              \*   \*   \*   6
  Ito et al[@b12-ott-10-3261]         2010        \*              \*        \*              \*   \*   \*   6
  Jovanovic et al[@b32-ott-10-3261]   2015        \*              \*        \*              \*   \*   \*   6
  Gnemmi et al[@b14-ott-10-3261]      2014        \*              \*        \*         \*   \*   \*   \*   7
  Miyauchi et al[@b22-ott-10-3261]    2013        \*              \*        \*              \*   \*        5
  Chen et al[@b20-ott-10-3261]        2011        \*              \*        \*              \*   \*   \*   6
  Wang et al[@b33-ott-10-3261]        1996        \*              \*        \*              \*   \*   \*   6
  Tisell et al[@b26-ott-10-3261]      2003        \*              \*        \*              \*   \*   \*   6

**Notes:** A: representative of the exposed cohort; B: selection of the nonexposed cohort; C: ascertainment of exposure; D: demonstration that outcome of interest was not present at the start of study; E: comparability of cohorts on the basis of the design or analysis; F: assessment of outcome; G: adequacy of follow-up for outcomes to occur (≥2 years or outcomes occurred in all patients); H: adequacy of follow-up of cohorts (follow-up rate ≥75%).

**Abbreviation:** NOS, Newcastle--Ottawa scale.
